AU2017256910B2 - Optogenetic visual restoration using Chrimson - Google Patents

Optogenetic visual restoration using Chrimson Download PDF

Info

Publication number
AU2017256910B2
AU2017256910B2 AU2017256910A AU2017256910A AU2017256910B2 AU 2017256910 B2 AU2017256910 B2 AU 2017256910B2 AU 2017256910 A AU2017256910 A AU 2017256910A AU 2017256910 A AU2017256910 A AU 2017256910A AU 2017256910 B2 AU2017256910 B2 AU 2017256910B2
Authority
AU
Australia
Prior art keywords
protein
gly
chrimson
glu
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017256910A
Other languages
English (en)
Other versions
AU2017256910A1 (en
Inventor
Romain CAPLETTE
Deniz DALKARA
Melissa DESROSIERS
Anne DOUAR
Jens Duebel
Gregory Gauvain
Serge Picaud
Didier Pruneau
Jose Sahel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique
Institut National de la Santé et de la Recherche Médicale
Sorbonne Université
Gensight Biologics SA
Original Assignee
Centre National de la Recherche Scientifique
Institut National de la Santé et de la Recherche Médicale
Sorbonne Université
Gensight Biologics SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale, Sorbonne Université, Gensight Biologics SA filed Critical Centre National de la Recherche Scientifique
Publication of AU2017256910A1 publication Critical patent/AU2017256910A1/en
Assigned to CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, GENSIGHT BIOLOGICS SA, Sorbonne Université reassignment CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE Amend patent request/document other than specification (104) Assignors: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, GENSIGHT BIOLOGICS SA, INSTITUT NATIONAL DE LA SANTE DE LA RECHERCHE MEDICALE, Sorbonne Université
Application granted granted Critical
Publication of AU2017256910B2 publication Critical patent/AU2017256910B2/en
Priority to AU2022204884A priority Critical patent/AU2022204884A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/405—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from algae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/864—Parvoviral vectors, e.g. parvovirus, densovirus
    • C12N15/8645—Adeno-associated virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Marine Sciences & Fisheries (AREA)
AU2017256910A 2016-04-29 2017-04-28 Optogenetic visual restoration using Chrimson Active AU2017256910B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2022204884A AU2022204884A1 (en) 2016-04-29 2022-07-07 Optogenetic visual restoration using Chrimson

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662329692P 2016-04-29 2016-04-29
US62/329,692 2016-04-29
PCT/IB2017/000663 WO2017187272A1 (en) 2016-04-29 2017-04-28 Optogenetic visual restoration using chrimson

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2022204884A Division AU2022204884A1 (en) 2016-04-29 2022-07-07 Optogenetic visual restoration using Chrimson

Publications (2)

Publication Number Publication Date
AU2017256910A1 AU2017256910A1 (en) 2018-11-22
AU2017256910B2 true AU2017256910B2 (en) 2022-04-07

Family

ID=59253830

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2017256910A Active AU2017256910B2 (en) 2016-04-29 2017-04-28 Optogenetic visual restoration using Chrimson
AU2022204884A Abandoned AU2022204884A1 (en) 2016-04-29 2022-07-07 Optogenetic visual restoration using Chrimson

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2022204884A Abandoned AU2022204884A1 (en) 2016-04-29 2022-07-07 Optogenetic visual restoration using Chrimson

Country Status (8)

Country Link
US (2) US20190269755A1 (cg-RX-API-DMAC10.html)
EP (1) EP3448411A1 (cg-RX-API-DMAC10.html)
JP (1) JP6942789B2 (cg-RX-API-DMAC10.html)
KR (1) KR102466887B1 (cg-RX-API-DMAC10.html)
CN (1) CN110267673B (cg-RX-API-DMAC10.html)
AU (2) AU2017256910B2 (cg-RX-API-DMAC10.html)
CA (1) CA3025975A1 (cg-RX-API-DMAC10.html)
WO (1) WO2017187272A1 (cg-RX-API-DMAC10.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12599670B2 (en) 2014-12-12 2026-04-14 The Trustees Of The University Of Pennsylvania Composition comprising three-dimensional astrocyte bundles of bi-polar and aligned astrocyte processes and a method of making thereof
EP3442409A4 (en) 2016-04-14 2019-11-13 The Trustees of The University of Pennsylvania IMPLANTABLE LIVING ELECTRODES AND METHOD FOR USE THEREOF
EP3693060A1 (en) 2019-02-05 2020-08-12 Gensight Biologics Method for controlling an optogenetic device using a command law for the radiant power of a light source and associated devices
EP3693061A1 (en) 2019-02-05 2020-08-12 Gensight Biologics Method for controlling an optogenetic device using filtering and associated devices
EP3733139A1 (en) 2019-05-02 2020-11-04 Gensight Biologics Viewing apparatus and method for projecting a light signal
WO2021132903A1 (ko) * 2019-12-26 2021-07-01 고려대학교 산학협력단 광유전학 기법을 이용한 알츠하이머 질환 뇌에서의 뇌파 손상 회복 방법
WO2023158839A1 (en) * 2022-02-18 2023-08-24 The Trustees Of The University Of Pennsylvania Tissue engineered spinal tracts for functional regeneration after spinal cord injury
JP2025528188A (ja) 2022-08-11 2025-08-26 インスティテュート オブ モレキュラー アンド クリニカル オフサルモロジー バーゼル （アイオービー） ヒト錐体光受容体オプトジェネティクス構築物
CN119827471B (zh) * 2025-02-14 2025-10-03 中山大学中山眼科中心 一种体内追踪外段蛋白运输的方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10216005A1 (de) 2002-04-11 2003-10-30 Max Planck Gesellschaft Verwendung von biologischen Photorezeptoren als direkt lichtgesteuerte Ionenkanäle
JP2009502140A (ja) 2005-07-22 2009-01-29 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 光活性化陽イオンチャネルおよびその使用
US8470790B2 (en) * 2006-05-04 2013-06-25 Wayne State University Restoration of visual responses by in vivo delivery of rhodopsin nucleic acids
EP1891976A1 (en) 2006-08-23 2008-02-27 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute for Biomedical Research Use of light sensitive genes
CA2713755A1 (en) * 2008-02-07 2009-08-13 Ceregene, Inc. Rescue of photoreceptors by intravitreal administration of an expression vector encoding a therapeutic protein
EP2679246A3 (en) 2008-04-18 2014-02-26 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Novel therapeutical tools and methods for treating blindness
DK3693025T3 (da) 2011-04-22 2022-01-10 Univ California Adenoassocierede virus-virioner med variant capsid og fremgangsmåder til anvendelse heraf
WO2013071231A1 (en) * 2011-11-12 2013-05-16 Massachusetts Institute Of Technology Channelrhodopsins for optical control of cells
WO2015161308A1 (en) * 2014-04-18 2015-10-22 Massachusetts Institute Of Technology Mutant channelrhodopsins with altered ion selectivity
US10882892B2 (en) * 2014-08-05 2021-01-05 Massachusetts Institute Of Technology Channelrhodopsin variants and uses thereof
JP2018533768A (ja) * 2015-11-05 2018-11-15 インスコピックス， インコーポレイテッド 光遺伝学撮像のためのシステムおよび方法
JP6966442B2 (ja) * 2015-12-04 2021-11-17 ソルボンヌ・ユニヴェルシテSorbonne Universite プロモーター及びその使用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Klapoetke et al., 2014, Nat Methods, 11(3), 338-346. *

Also Published As

Publication number Publication date
WO2017187272A1 (en) 2017-11-02
KR20190058383A (ko) 2019-05-29
WO2017187272A8 (en) 2018-12-13
JP6942789B2 (ja) 2021-09-29
CA3025975A1 (en) 2017-11-02
JP2019518073A (ja) 2019-06-27
AU2017256910A1 (en) 2018-11-22
US20190269755A1 (en) 2019-09-05
US20240165198A1 (en) 2024-05-23
AU2022204884A1 (en) 2022-07-28
CN110267673B (zh) 2023-05-16
CN110267673A (zh) 2019-09-20
KR102466887B1 (ko) 2022-11-11
EP3448411A1 (en) 2019-03-06

Similar Documents

Publication Publication Date Title
US20240165198A1 (en) Optogenetic visual restoration using chrimson
RU2758211C2 (ru) Synp161, промотор для специфической экспрессии генов в палочковых фоторецепторах
US8754048B2 (en) Light-receiving channel rhodopsin having improved expression efficiency
JP7348176B2 (ja) 霊長類網膜色素上皮細胞特異的プロモーター
JP7023279B2 (ja) ＳｙｎＰ１９８、方向選択性網膜神経節細胞内での遺伝子の特異的発現のためのプロモーター
JP6969798B2 (ja) ＳｙｎＰ１６０、桿体光受容器における遺伝子の特異的発現のためのプロモーター
JP7058220B2 (ja) ＳｙｎＰ１５９、桿体光受容器における遺伝子の特異的発現のためのプロモーター
JP7390290B2 (ja) 霊長類網膜色素上皮細胞特異的プロモーターＳｙｎＰ６１
JP7075341B2 (ja) ＳｙｎＰ１６２、桿体光受容器における遺伝子の特異的発現のためのプロモーター
JP2018076377A (ja) ロドプシン拡散のインビボ送達による視覚応答の回復
US11254934B2 (en) Promoter for the specific expression of genes in retinal endothelial cells
WO2020084539A1 (en) Synp57 (proa14), a promoter for the specific expression of genes in photoreceptors
JP2022505517A (ja) 網膜神経節細胞中の遺伝子の特異的発現のためのプロモーターＳｙｎＰ１５１（ＰｒｏＣ２９）
JP2022517688A (ja) 網膜神経節細胞中の遺伝子の特異的発現のためのプロモーターＳｙｎＰ３５（ＰｒｏＣ８）
JP2020503852A (ja) インターニューロン中の遺伝子の特異的発現のためのプロモーターｓｙｎｐ１０７
WO2020152626A1 (en) Synp166 (proa36), a promoter for the specific expression of genes in photoreceptors
JP2020501538A (ja) インターニューロン中の遺伝子の特異的発現のためのプロモーターｓｙｎｐｉ
CN115335525B (zh) 经修饰的通道视紫红质

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE

Free format text: FORMER NAME(S): SORBONNE UNIVERSITE; GENSIGHT BIOLOGICS SA; CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE; INSTITUT NATIONAL DE LA SANTE DE LA RECHERCHE MEDICALE

Owner name: GENSIGHT BIOLOGICS SA

Free format text: FORMER NAME(S): SORBONNE UNIVERSITE; GENSIGHT BIOLOGICS SA; CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE; INSTITUT NATIONAL DE LA SANTE DE LA RECHERCHE MEDICALE

Owner name: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE M

Free format text: FORMER NAME(S): SORBONNE UNIVERSITE; GENSIGHT BIOLOGICS SA; CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE; INSTITUT NATIONAL DE LA SANTE DE LA RECHERCHE MEDICALE

Owner name: SORBONNE UNIVERSITE

Free format text: FORMER NAME(S): SORBONNE UNIVERSITE; GENSIGHT BIOLOGICS SA; CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE; INSTITUT NATIONAL DE LA SANTE DE LA RECHERCHE MEDICALE

FGA Letters patent sealed or granted (standard patent)